Halting the Inflammation Process

  • KO mouse protected from hepatic steatosis on HFD
  • Inhibitor lowers liver cholesterol and triglycerides in mouse in vivo model
  • Inhibitor decreases liver enzymes in several NASH models
  • IST POC trial with known inhibitor confirms liver fat loss
  • Documented human safety for this target
  • Implicated as I/O approach to cancer
  • Active site SBDD enabled

Lorem Ipsum Dolore Sectum